Ceapro Inc V.CZO

New Press Release - Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline developmentEDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage...read article.

[lscfa]

Maybe if Gagnon did not have the base business cash flow he would be more prudent in spending. G&A blowing up...     Revenues Gross profit Gross margin Cash flow ops R&D G&A CFO b/f R&D Q1 23

[prophetoffactz]

In SG&A legal fees increased to $343,000 in the current quarter vs. only $3,000 in the prior year.  People here wanted deals... Looks like the company has been actively evaluating deals... "...in the current quarter, directors were engaged in assessing different strategic growth opportunities which resulted in significant legal fees incurred mostly for conducting preliminary due

[prophetoffactz]

I think we may now know why there was that extraordinary revenue surge in Q1 and Q2 last year. J&J was preparing for the split-off of Aveeno and Neutrogena into a seperate company. In the three quarters since CZO's revenue has only run at an annualized rate of ~$14.22 million which is about 76% of last year's $18.84 million revenue. Gilles expected growth from Symrise earlier this year

[Hopeforthebest]

JUST PURE BULL